A detailed history of Core Cap Advisors, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Core Cap Advisors, LLC holds 23 shares of PRTA stock, worth $334. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23
Previous 23 -0.0%
Holding current value
$334
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$19.54 - $26.15 $449 - $601
23 New
23 $0
Q4 2022

Feb 10, 2023

BUY
$52.05 - $65.0 $1,197 - $1,495
23 New
23 $1,000
Q2 2022

Aug 11, 2022

BUY
$22.73 - $39.98 $250 - $439
11 New
11 $0
Q1 2022

Apr 29, 2022

SELL
$30.27 - $49.22 $332 - $541
-11 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$42.11 - $73.26 $463 - $805
11 New
11 $1,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $683M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.